Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 7/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.37 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27229236 | 0.87 | IRAK4 (0.47) | PIM1IRAK4CDC25ACDC25BMAP3K5 | |
| SCHEMBL27229200 | 0.84 | CLK2 (0.48) | PIM1IRAK4CDC25ACDC25BCLK2 | |
| SCHEMBL27229246 | 0.83 | PIM1 (0.40) | PIM1IRAK4CDC25ACDC25BMAP3K5 | |
| SCHEMBL27229322 | 0.82 | PIM1 (0.40) | PIM1IRAK4CDC25ACDC25BMAP3K5 | |
| SCHEMBL27029407 | 0.80 | IRAK4 (0.49) | PIM1IRAK4CDC25ACDC25BROCK1 | |
| SCHEMBL27229211 | 0.78 | CLK2 (0.42) | PIM1IRAK4MAP3K5RETCDK2 | |
| SCHEMBL2586955 | 0.78 | MAOA (0.39) | PIM1MAP3K5RETCDK2GSK3B | |
| SCHEMBL2590821 | 0.76 | ALDH1A1 (0.45) | PIM1CLK2LRRK2 | |
| SCHEMBL27229383 | 0.75 | CLK2 (0.50) | PIM1IRAK4MAP3K5RETCDK2 | |
| SCHEMBL27229381 | 0.75 | PIM1 (0.43) | PIM1MAP3K5RETCDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174679-A1 | HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174679-A1 | HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | PIM1 1824/4885IRAK4 267/4885CDC25A 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.